> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Workshop on Adenoviral Infection Drug Development
- URL: https://www.fdaweb.com/workshop-on-adenoviral-infection-drug-development/
- Published: 2019-05-01T12:00:00.000Z
- Updated: 2026-09-15T01:23:46.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144003

*Federal Register* notice: FDA has announced an 8/8 public workshop entitled “Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients” that is intended to discuss the scientific and clinical trial design considerations for development of antiviral products to treat adenoviral infection. Discussions are also planned around the following topics: Trial design considerations (e.g., trial endpoints, trial populations, treatment strategies, risk/benefit considerations, ethical considerations, virologic testing considerations); and diagnostic assay(s) considerations. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-08993.pdf?ref=fdaweb.com).